We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00568490
Recruitment Status : Recruiting
First Posted : December 6, 2007
Last Update Posted : June 14, 2022
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University

Brief Summary:
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Condition or disease Intervention/treatment
Head and Neck Cancer Lung Cancer Lip Cancer Lip Neoplasms Head and Neck Cancers Procedure: Tumor biopsy Procedure: Phlebotomy

Detailed Description:

The endpoints of the study are

  1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.
  2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Actual Study Start Date : September 1, 1998
Estimated Primary Completion Date : June 15, 2023
Estimated Study Completion Date : December 15, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Intervention Details:
  • Procedure: Tumor biopsy
    For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
  • Procedure: Phlebotomy
    Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
    Other Name: Blood draw

Primary Outcome Measures :
  1. Identification of Secreted Markers for Tumor Hypoxia through tissue collection [ Time Frame: before therapy, weekly during therapy ]

Biospecimen Retention:   Samples Without DNA
blood, tumor tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Newly diagnosed patients with head and neck cancer

Inclusion Criteria:

  • Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
  • Able to sign a Stanford IRB approved consent form

Exclusion criteria:

  • Refuse or unable to sign an IRB approved consent form.
  • Refuse to be contacted in the future for follow up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00568490

Layout table for location contacts
Contact: Rachel Freiberg rachelf@stanford.edu

Layout table for location information
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Rachel Freiberg    650-725-0438    rachelf@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Quynh-Thu Le         
Sub-Investigator: Amato Giaccia         
Sub-Investigator: Richard L Goode         
Sub-Investigator: Harlan Pinto         
Sub-Investigator: Dr. Billy W. Loo Jr. M.D. Ph.D.         
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Quynh-Thu Le Stanford University
Layout table for additonal information
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00568490    
Obsolete Identifiers: NCT00185822
Other Study ID Numbers: ENT0016
15310; CA67166
73995 ( Other Identifier: Stanford University Alternate IRB Approval Number )
SU-11052007-801 ( Other Identifier: Stanford University )
First Posted: December 6, 2007    Key Record Dates
Last Update Posted: June 14, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Head and Neck Neoplasms
Lip Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Mouth Neoplasms
Lip Diseases
Mouth Diseases
Stomatognathic Diseases